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Addendum
SUMMARY
The number of people with overweight is increasing rapidly worldwide, reaching
pandemic proportions. In 2014, 39% of the adults were overweight and 13% were obese.
A combination of excessive food intake (high-caloric, high-fat) and low physical activity
are the primary contributors to the development of overweight (1). Overweight is
associated with the development of chronic metabolic disease such as type 2 diabetes
mellitus (T2DM). An important characteristic of T2DM is that the metabolic effects of
insulin on glucose metabolism are blunted (2). As the prevalence of T2DM is tightly
linked to obesity, also T2DM, just like overweight, is increasing dramatically worldwide.
Recent estimates reported 171 million people worldwide diagnosed with T2DM in the
year 2000 and expected to increase towards 366 million in 2030 (3). Since T2DM is
associated with reduced quality of life, decreased life expectancy, and increased risk of
morbidities such as cardiovascular diseases, the diabetes-related costs are a major
burden on our health care systems. Therefore, it is important to increase our
understanding of this disease to improve prevention and cure.
Decreased metabolic flexibility is an early hallmark in the development of T2DM.
Acetylcarnitine has recently been suggested as a very important metabolite in
maintaining metabolic flexibility, and subsequently glucose homeostasis and insulin
sensitivity (4-7). Free carnitine availability is identified as being crucial in acetylcarnitine
formation and maintaining metabolic flexibility (4, 5, 8).
In chapter 2 we investigated the role of acylcarnitines in a human intervention that is
expected to modify substrate metabolism and metabolic flexibility. The effects of three
weeks isoenergetic high-fat feeding on metabolic flexibility and insulin sensitivity in
overweight male volunteers are described. High fat diet is known to decrease metabolic
flexibility, and we therefore investigated if changes in free carnitine availability,
acetylcarnitine, or other carnitine species could explain the earlier reported decrease in
metabolic flexibility. Acylcarnitines and free carnitine were unchanged in response to the
diet. However, we revealed that the muscle concentration of free carnitine was related to
the metabolic response with the diet and therefore, volunteers with low free carnitine
availability at the beginning of the dietary intervention showed the most pronounced
decrease in insulin sensitivity and metabolic flexibility suggesting free carnitine
availability as a predictive marker for metabolic response to a change in diet.
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This gave rise to the hypothesis that enhancing free carnitine in metabolic compromised
humans might be a good strategy to combat metabolic inflexibility and insulin resistance
by increasing the capacity to form acetylcarnitine. Possible strategies to enhance free
carnitine availability could be intravenous infusion or oral supplementation of carnitine.
In chapter 3, we investigated if acute carnitine infusion during simultaneous lipid
infusion could alleviate lipid-induced insulin resistance and metabolic inflexibility in
healthy young males by increasing free carnitine availability. As expected, the
intravenous lipid infusion elevated plasma free fatty acid concentration and resulted in a
hampered insulin sensitivity and metabolic flexibility in healthy, insulin sensitive
volunteers. Intravenous infusion of carnitine in addition to lipid elevated plasma free
carnitine availability. However, against expectations, carnitine infusion did not increase
skeletal muscle free carnitine availability possibly due to insulin resistance of the OCTN2
receptor involved in skeletal muscle carnitine uptake. In line with the lack of increase in
skeletal muscle free carnitine availability, lipid-induced metabolic inflexibility and insulin
resistance was not rescued by carnitine administration.
Next to the short-term elevation in carnitine availability by intravenous infusions, we also
aimed to investigate the longer term effect upon a five-week intervention with oral
carnitine supplementation. Therefore, chapter 4 describes the results of a double-blind,
randomized placebo-controlled trial investigating if oral carnitine supplementation
improves metabolic flexibility and insulin resistance in volunteers with impaired glucose
tolerance. Furthermore, it was investigated whether this is mediated by increased
formation of acetylcarnitine. Carnitine supplementation had very pronounced effects on
metabolic flexibility in impaired glucose tolerant volunteers, and in fact was able to
completely restore metabolic flexibility. Carnitine supplementation enhanced the increase
in acetylcarnitine concentration in resting muscle over the day as well as the capacity to
form acetylcarnitine with exercise. These changes in acetylcarnitine formation may be
underlying the beneficial effects on metabolic flexibility. Taken together, carnitine
supplementation may be an interesting aid in improving disturbed metabolism in
subjects prone to develop type 2 diabetes mellitus.
In chapter 5, we developed an alternative Magnetic Resonance Spectroscopy (MRS)
sequence to detect acetylcarnitine concentration in vivo. Previously, we reported that
acetylcarnitine can be detected by MRS, using long echo times (TE=350 ms) as lipid
resonances are suppressed due to short T2 relaxation. In chapter 3 and 4 we applied this
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MR technique. However, the spectra with TE=350 ms that were analyzed in chapter 4
still showed considerable lipid contamination in overweight participants due to strong
adipose tissue marbling of muscle in these subjects (and therefore, even longer echo
times were used for acetylcarnitine quantification in chapter 4). Thus, more pronounced
T2-weighting proved necessary in this typical overweight population to sufficiently
suppress adipose tissue signal and determine acetylcarnitine. Therefore, a sequence that
also makes use of the difference in T1 between acetylcarnitine- and lipid resonances was
developed. This new (alternative) methodology allows to better suppress the lipid signal,
which is especially important in subjects with high abundance of intramuscular fat. This
allows more accurate quantification of acetylcarnitine concentrations at TE=350ms in
this population in future studies.
In chapter 6, we investigated the role of acylcarnitines in a human intervention with
resveratrol. Resveratrol has been shown to improve mitochondrial function and
metabolic health in obese humans, and provides another model to investigate the
relationship between acylcarnitines and metabolic flexibility in humans. The effects of
the food supplement resveratrol on insulin sensitivity, metabolic flexibility, mitochondrial
function and skeletal muscle acylcarnitine species in impaired glucose tolerant subjects
were investigated but while mitochondrial function was stimulated in response to
resveratrol, no effects of resveratrol were found on other metabolic health parameters
and in line, acylcarnitine concentrations remained unchanged.
While up to now, reduced acetylcarnitine formation was only reported in metabolic
inflexible and insulin resistant rodents. This thesis shows that the formation of
acetylcarnitine is also reduced in humans with compromised metabolic health. Based on
this association between free carnitine availability and metabolic flexibility and insulin
sensitivity, improving free carnitine availability might be a very potent target to improve
metabolic flexibility, insulin sensitivity and glucose tolerance in subject with hampered
carnitine availability. Although lipid-induced metabolic inflexibility and insulin resistance
could not be rescued by carnitine administration, supplementation with carnitine had
very pronounced effects of on metabolic flexibility in impaired glucose tolerant
volunteers, and in fact can completely restore metabolic flexibility. Therefore, carnitine
supplementation may be an interesting aid in improving disturbed metabolism in
subjects prone to develop type 2 diabetes mellitus.
184
Addendum
REFERENCES
1. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to
2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million
children, adolescents, and adults. Lancet (London, England). 2017.
2. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a
reexamination. Diabetes. 2000;49(5):677-83.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the
year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047-53.
4. Muoio DM, Noland RC, Kovalik JP, Seiler SE, Davies MN, DeBalsi KL, et al. Muscle-specific
deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility.
Cell metabolism. 2012;15(5):764-77.
5. Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, Ilkayeva O, et al. Carnitine insufficiency
caused by aging and overnutrition compromises mitochondrial performance and metabolic
control. The Journal of biological chemistry. 2009;284(34):22840-52.
6. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of
carnitine in the regulation of fuel metabolism in skeletal muscle. The Journal of physiology.
2007;581(Pt 2):431-44.
7. Muoio DM. Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock.
Cell. 2014;159(6):1253-62.
8. Power RA, Hulver MW, Zhang JY, Dubois J, Marchand RM, Ilkayeva O, et al. Carnitine
revisited: potential use as adjunctive treatment in diabetes. Diabetologia. 2007;50(4):824-
32.
185
